Founded in 2009, Coyote Bioscience Co., Ltd. is a national high-tech enterprise specializing in molecular diagnostic point-of-care testing (POCT). The company focuses on collaborative product development across various fields, including instruments, reagents, system platforms, artificial intelligence, and big data. Headquartered in Beijing, Coyote has established R&D centers in Zhongguancun, Beijing, and Silicon Valley, USA, along with production facilities in Beijing, Tianjin, and Jiangsu, and third-party testing laboratories in Beijing and Tianjin. Driven by technological innovation, Coyote has successfully developed three generations of advanced molecular diagnostic products. The company has built a robust R&D and mass production platform for molecular POCT technologies, boasting independent intellectual property rights and domestically manufactured core components that meet internationally advanced standards. Utilizing a fully automated molecular POCT diagnostic robot platform, Coyote targets infectious diseases, women’s and children’s health, and precision medicine, offering intelligent, customized, and decentralized diagnostic solutions. Coyote’s products are available in over 65 countries and regions worldwide. The company has been granted 95 domestic and international patents and has obtained ISO 13485 quality management system certification. The products are certified by CE IVD, China NMPA, Brazil ANVISA, and other countries' registrations.